Nexalin Technology, Inc.

Nexalin Technology, Inc. is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Houston, Texas and currently employs 8 full-time employees. The company went IPO on 2022-09-16. Nexalin Technology, Inc. is a medical device company. The company engaged in design and development of neurostimulation products for mental health epidemics. The company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. The company has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. The company also operates PONM, which is a digital health platform.